Turnstone Biologics Corp.
TSBX
$0.35
$0.0319.72%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | -22.12% | 1.78% | 27.02% | 4.90% | -12.10% |
| Gross Profit | 22.12% | -1.78% | -27.02% | -471.27% | -322.09% |
| SG&A Expenses | -26.83% | -17.11% | -7.13% | 21.55% | 1.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.42% | -2.97% | 0.94% | 8.41% | -8.84% |
| Operating Income | 23.42% | 2.97% | -0.94% | -9,462.44% | -125.28% |
| Income Before Tax | 27.55% | -2.86% | 0.94% | -139,992.86% | -21.70% |
| Income Tax Expenses | 606.06% | -2,372.73% | 133.33% | 119.51% | -1,200.00% |
| Earnings from Continuing Operations | 21.75% | 1.66% | 0.91% | -28,966.18% | -20.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.75% | 1.66% | 0.91% | -28,966.18% | -20.36% |
| EBIT | 23.42% | 2.97% | -0.94% | -9,462.44% | -125.28% |
| EBITDA | 22.32% | 1.94% | -2.07% | -2,270.11% | -159.26% |
| EPS Basic | 22.18% | 25.74% | 87.76% | 83.38% | 86.03% |
| Normalized Basic EPS | 12.98% | 22.33% | 87.76% | -495.18% | 74.14% |
| EPS Diluted | 22.18% | 25.74% | 87.76% | 83.38% | 86.03% |
| Normalized Diluted EPS | 12.98% | 22.33% | 87.76% | -495.18% | 74.14% |
| Average Basic Shares Outstanding | 0.55% | 32.42% | 708.99% | 725.98% | 760.26% |
| Average Diluted Shares Outstanding | 0.55% | 32.42% | 708.99% | 725.98% | 760.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |